Insider Buying: Anixa Biosciences (NASDAQ:ANIX) Director Purchases $13,800.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) Director Arnold Baskies bought 5,000 shares of the firm’s stock in a transaction dated Thursday, September 24th. The shares were acquired at an average price of $2.76 per share, for a total transaction of $13,800.00. Following the completion of the transaction, the director owned 140,572 shares in the company, valued at $387,978.72. This represents a 3.69% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Anixa Biosciences Stock Up 2.8%

NASDAQ:ANIX opened at $2.93 on Thursday. Anixa Biosciences Inc has a 12-month low of $2.32 and a 12-month high of $5.46. The firm has a market capitalization of $101.85 million, a PE ratio of -9.16 and a beta of 0.51. The firm has a 50-day moving average price of $3.20 and a 200 day moving average price of $2.97.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). On average, research analysts expect that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Anixa Biosciences during the second quarter worth approximately $559,000. GSA Capital Partners LLP bought a new position in Anixa Biosciences in the 2nd quarter worth approximately $329,000. Renaissance Technologies LLC boosted its position in Anixa Biosciences by 13.6% in the 1st quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock valued at $158,000 after buying an additional 7,300 shares during the last quarter. Kestra Advisory Services LLC increased its stake in shares of Anixa Biosciences by 96.2% in the 1st quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock valued at $132,000 after buying an additional 25,000 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in shares of Anixa Biosciences during the second quarter worth $133,000. 29.13% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ANIX has been the topic of a number of analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. HC Wainwright reduced their price target on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, September 22nd. Zacks Research lowered shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Weiss Ratings raised shares of Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Anixa Biosciences presently has an average rating of “Hold” and an average price target of $8.00.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company’s research programs are designed to use the immune system to prevent or treat serious illnesses.

Anixa’s cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.

In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.